Please ensure Javascript is enabled for purposes of website accessibility

Why Mallinckrodt Stock Is Tanking Today

By Keith Speights – May 21, 2019 at 12:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company filed a lawsuit to stop a federal decision that could be very bad news for its top drug.

What happened

Shares of Mallinckrodt (MNK) were tanking by 26.4% as of 10:49 a.m. EDT on Tuesday. The drugmaker announced earlier in the day that it had filed a lawsuit against the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) in an attempt to set aside a recent CMS decision that the company says would eliminate its net sales of Acthar Gel to Medicaid.

So what

CMS intends to require that Mallinckrodt change the base date average manufacturer price (AMP) that's used to calculate Medicaid drug rebates for Acthar. There's a complicated process involved in establishing drug prices for Medicaid patients using this base date AMP. The bottom line for Mallinckrodt is that the change CMS wants could cause the company to pay as much as $600 million in retroactive rebates plus prospective rebate increases of around 10% of Acthar Gel annual net sales.

Businessman looking at red line going through the floor

Image source: Getty Images.

This CMS decision is a huge blow for Mallinckrodt, especially because it's a surprise. Its executives didn't mention anything about the potential for such an adverse decision in the company's Q1 conference call earlier this month. The company even raised its full-year 2019 earnings guidance, reflecting optimism.

Acthar Gel is Mallinckrodt's top-selling product, currently generating more than 28% of the company's total sales. Any significant hit to Acthar would make a major impact on its top and bottom lines.

The company thinks that it's on solid legal ground in its lawsuit against HHS and CMS, though. Mallinckrodt maintains that CMS "attempts to reverse without explanation the Agency's 2012 express, written approval (on two occasions) of the base date AMP used since 2013." 

Now what

Investors will have to wait and see what happens in the courts. Mallinckrodt doesn't plan to change it full-year 2019 guidance or put aside any reserves related to the Medicaid pricing at this point. 

It's possible that we could see a rebound of sorts with the stock in the coming days and weeks. Some investors could think that today's sell-off is overdone based on the possibility that Mallinckrodt will prevail in its case against HHS and CMS. For now, though, this stock is probably one that's best to watch from the sidelines as the drama unfolds. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mallinckrodt Stock Quote
Mallinckrodt
MNK

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.